Table 6.
Disaggregated components of the clinical effectiveness measures between the matched treatment groups during the outcome year
| Outcome | EH (n=979) |
OH (n=979) |
P-valuea |
|---|---|---|---|
| Courses of oral steroids | |||
| 0, n (%) | 883 (90.2%) | 895 (91.4%) | 0.224 |
| 1, n (%) | 76 (7.8%) | 70 (7.2%) | |
| 2+, n (%) | 20 (2.0%) | 14 (1.4%) | |
| SABA dosage (μg/day) | |||
| ≤200, n (%) | 508 (51.9%) | 460 (47.0%) | <0.001 |
| >200, n (%) | 471 (48.1%) | 519 (53.0%) | |
| Increase in ICS dosage | |||
| Yes, n (%) | 125 (12.8%) | 76 (7.8%) | <0.001 |
| Change in ICS drug | |||
| Yes, n (%) | 171 (17.5%) | 94 (9.6%) | <0.001 |
| Change in ICS device | |||
| Yes, n (%) | 217 (22.2%) | 112 (11.4%) | <0.001 |
| Additional therapy | |||
| Any, n (%) | 113 (11.5%) | 96 (9.8%) | 0.210 |
| BUD-FOR, n (%) | 49 (5.0%) | 30 (3.1%) | 0.034 |
Notes:
a
Conditional logistic regression. Easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant (P<0.05).
Abbreviations: BUD-FOR, budesonide-formoterol as fixed-dose combination inhaler; EH, Easyhaler®; OH, other inhalers; ICS, inhaled corticosteroid; SABA, short-acting β2 receptor agonist.